The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Primary and Secondary Prevention of Cardiovascular Disease
Open accessAbstract
Background This guideline focuses on long-term administration of antithrombotic drugs designed for primary and secondary prevention of cardiovascular disease, including two new antiplatelet therapies. Methods The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. Results We present 23 recommendations for pertinent clinical questions. For primary prevention of cardiovascular disease, we suggest low-dose aspirin (75-100 mg/d) in patients aged > 50 years over no aspirin therapy (Grade 2B). For patients with established coronary artery disease, defined as patients 1-year post-acute coronary syndrome, with prior revascularization, coronary stenoses > 50% by coronary angiogram, and/or evidence for cardiac ischemia on diagnostic testing, we recommend long-term low-dose aspirin or clopidogrel (75 mg/d) (Grade 1A). For patients with acute coronary syndromes who undergo percutaneous coronary intervention (PCI) with stent placement, we recommend for the first year dual antiplatelet therapy with low-dose aspirin in combination with ticagrelor 90 mg bid, clopidogrel 75 mg/d, or prasugrel 10 mg/d over single antiplatelet therapy (Grade 1B). For patients undergoing elective PCI with stent placement, we recommend aspirin (75-325 mg/d) and clopidogrel for a minimum duration of 1 month (bare-metal stents) or 3 to 6 months (drug-eluting stents) (Grade 1A). We suggest continuing low-dose aspirin plus clopidogrel for 12 months for all stents (Grade 2C). Thereafter, we recommend single antiplatelet therapy over continuation of dual antiplatelet therapy (Grade 1B). Conclusions Recommendations continue to favor single antiplatelet therapy for patients with established coronary artery disease. For patients with acute coronary syndromes or undergoing elective PCI with stent placement, dual antiplatelet therapy for up to 1 year is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence supports use of either ticagrelor or clopidogrel if no percutaneous coronary intervention was performed and clopidogrel, ticagrelor, or prasugrel if a percutaneous coronary intervention was performed (199).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [199]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence supports use of either ticagrelor or clopidogrel if no percutaneous coronary intervention was performed and clopidogrel, ticagrelor, or prasugrel if a percutaneous coronary intervention was performed (187).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [187]
In the citing paper
“Evidence supports use of either ticagrelor or clopidogrel if no percutaneous coronary intervention was performed and clopidogrel, ticagrelor , or prasugrel if a percutaneous coronary intervention was performed (162).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [162]
In the citing paper
“Co-prescription of OAC with antiplatelet therapy, in particular triple therapy, 1501 increases the absolute risk of major haemorrhage.445,517,518”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [517]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm
Lip, G. Y. H., Wrigley, B., & Pisters, R. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003333 · Cited by 32
RetractedPrediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Self-citationHansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 1
- Wilson, 1998, Prediction of coronary artery disease using risk factor categories, Circulation, 97, 1837, 10.1161/01.CIR.97.18.1837 · DOI · Paper page
Cited by
Sorted by citations
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,439
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Self-citationKernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C.-T., Fesmire, F. M., Franklin, B. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,802
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C.-T., Fesmire, F. M., Franklin, B. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182742c84 · Cited by 2,258
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C.-T., Fesmire, F. M., Franklin, B. A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.018 · Cited by 1,777
Guyatt, G. H., Akl, E. A., Crowther, M. A., Gutterman, D. D., & Schünemann, H. J. (2012) · CHEST Journal · doi:10.1378/chest.1412s3 · Cited by 1,545
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht149 · Cited by 1,455
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R. A., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M. P., Werring, D. J., et al. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.07.040 · Cited by 963
Antithrombotic Therapy for Atrial Fibrillation
You, J. J., Singer, D. E., Howard, P. A., Lane, D. A., Eckman, M. H., Fang, M. C., Hylek, E. M., Schulman, S., Go, A. S., Hughes, M., et al. (2012) · CHEST Journal · doi:10.1378/chest.11-2304 · Cited by 933
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Bibbins-Domingo, K. B., & on behalf of the U.S. Preventive Services Task Force* (2016) · Annals of Internal Medicine · doi:10.7326/m16-0577 · Cited by 864
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.24776 · Cited by 721
Daskalopoulou, S. S., Rabi, D. M., Zarnke, K. B., Dasgupta, K., Nerenberg, K. A., Cloutier, L., Gelfer, M., Lamarre-Cliché, M., Milot, A., Bolli, P., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.02.016 · Cited by 690
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · CHEST Journal · doi:10.1378/chest.11-2294 · Cited by 539
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
(2017) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 505
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Lansberg, M. G., O'Donnell, M. J., Khatri, P., Lang, E., Nguyen‐Huynh, M. N., Schwartz, N. E., Sonnenberg, F. A., Schulman, S., Vandvik, P. O., Spencer, F. A., et al. (2012) · CHEST Journal · doi:10.1378/chest.11-2302 · Cited by 459
Self-citationDiabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
Beckman, J. A., Paneni, F., Cosentino, F., & Creager, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht142 · Cited by 434
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Arachidonic Acid Metabolism and Kidney Inflammation
Wang, T., Fu, X., Chen, Q., Patra, J. K., Wang, D., Wang, Z., & Gai, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153683 · Cited by 435
Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2012) · CHEST Journal · doi:10.1378/chest.11-2293 · Cited by 389
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
8. Cardiovascular Disease and Risk Management
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s011 · Cited by 329
The strategies and techniques of drug discovery from natural products
Zhang, L., Song, J., Kong, L., Yuan, T., Li, W., Zhang, W., Hou, B., Lü, Y., & Du, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107686 · Cited by 341
Dechanont, S., Maphanta, S., Butthum, B., & Kongkaew, C. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3592 · Cited by 284
Dasgupta, K., Quinn, R. R., Zarnke, K. B., Rabi, D. M., Ravani, P., Daskalopoulou, S. S., Rabkin, S. W., Trudeau, L., Feldman, R. D., Cloutier, L., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.02.002 · Cited by 270
Guirguis‐Blake, J., Evans, C. V., Senger, C. A., O’Connor, E., & Whitlock, E. P. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2113 · Cited by 264
Patrignani, P., & Patrono, C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.083 · Cited by 263
Patients with atrial fibrillation and coronary artery disease – Double trouble
Michniewicz, E., Młodawska, E., Łopatowska, P., Tomaszuk−Kazberuk, A., & Małyszko, J. (2017) · Advances in Medical Sciences · doi:10.1016/j.advms.2017.06.005 · Cited by 254
8. Cardiovascular Disease and Risk Management
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s011 · Cited by 239
9. Cardiovascular Disease and Risk Management
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s012 · Cited by 223
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Patrono, C., Morais, J., Baigent, C., Collet, J., Fitzgerald, D. J., Halvorsen, S., Rocca, B., Siegbahn, A., Storey, R. F., & Vilahur, G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.037 · Cited by 233
DiNicolantonio, J. J., Lavie, C. J., Fares, H., Menezes, A. R., & O'Keefe, J. H. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.02.007 · Cited by 217
The Role of Aspirin in the Prevention of Cardiovascular Disease
Ittaman, S., VanWormer, J. J., & Rezkalla, S. H. (2014) · Clinical Medicine & Research · doi:10.3121/cmr.2013.1197 · Cited by 211
Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies
Rodríguez, L. A. G., Martín‐Pérez, M., Hennekens, C. H., Rothwell, P. M., & Lanas, Á. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160046 · Cited by 201
Oldgren, J., Wallentin, L., Alexander, J. H., James, S., Jonelid, B., Steg, G., & Sundstrom, J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht049 · Cited by 198
Antithrombotic Therapy in Peripheral Artery Disease
Alonso‐Coello, P., Bellmunt-Montoya, S., McGorrian, C., Anand, S. S., Guzman, R., Criqui, M. H., Akl, E. A., Vandvik, P. O., Lansberg, M. G., Guyatt, G. H., et al. (2012) · CHEST Journal · doi:10.1378/chest.11-2307 · Cited by 199
Self-citationLeft Ventricular Thrombus Following Acute Myocardial Infarction
Camaj, A., Fuster, V., Giustino, G., Bienstock, S., Sternheim, D., Mehran, R., Dangas, G., Kini, A. S., Sharma, S. K., Halperin, J. L., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.01.011 · Cited by 208
Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease
Pasterkamp, G., den Ruijter, H. M., & Libby, P. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.166 · Cited by 178
Aspirin Therapy in Primary Cardiovascular Disease Prevention
Halvorsen, S., Andreotti, F., ten Berg, J. M., Cattaneo, M., COCCHERI, S., Marchioli, R., Morais, J., Verheugt, F. W. A., & Caterina, R. D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.049 · Cited by 167
Role of aspirin in primary prevention of cardiovascular disease
Patrono, C., & Baigent, C. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0225-y · Cited by 163
Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus
Capodanno, D., & Angiolillo, D. J. (2016) · Circulation · doi:10.1161/circulationaha.116.023164 · Cited by 158
Sudden Cardiac Death in the Older Athlete
Chugh, S. S., & Weiss, J. B. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.10.064 · Cited by 141
Left ventricular thrombi after STEMI in the primary PCI era: A systematic review and meta-analysis
Robinson, A. A., Jain, A., Gentry, M., & McNamara, R. L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.069 · Cited by 139
Chronic Treatment With Ticagrelor Limits Myocardial Infarct Size
Nanhwan, M. K., Ling, S., Kodakandla, M., Nylander, S., Ye, Y., & Birnbaum, Y. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304002 · Cited by 134
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin
Patrono, C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.012 · Cited by 137
Hsu, J. C., Maddox, T. M., Kennedy, K. F., Katz, D. F., Marzec, L., Lubitz, S. A., Gehi, A. K., Turakhia, M. P., & Marcus, G. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.581 · Cited by 133
Roles of Phenolic Compounds in the Reduction of Risk Factors of Cardiovascular Diseases
Mariane Lutz, R., Eduardo Fuentes, Q., Ávila, F., Alarcón, M. A., & Palomo, I. F. (2019) · Molecules · doi:10.3390/molecules24020366 · Cited by 130
Ye, Y., Birnbaum, G. D., Perez-Polo, J. R., Nanhwan, M. K., Nylander, S., & Birnbaum, Y. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305655 · Cited by 121
DiNicolantonio, J. J., Lavie, C. J., Fares, H., Menezes, A. R., & O’Keefe, J. H. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.11.031 · Cited by 111
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Left ventricular thrombosis: new perspectives on an old problem
Massussi, M., Scotti, A., Lip, G. Y. H., & Proietti, R. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa066 · Cited by 105
Chamberlain, J. J., Johnson, E. L., Leal, S., Rhinehart, A. S., Shubrook, J. H., & Peterson, L. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0222 · Cited by 105
Roles and Mechanisms of Hawthorn and Its Extracts on Atherosclerosis: A Review
Wu, M., Liu, L., Xing, Y., Yang, S., Li, H., & Cao, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00118 · Cited by 106
Lensing, A. W. A., Prins, M. H., Pesavento, R., Piccioli, A., Sartori, M., Tormene, D., Milan, M., Vedovetto, V., Noventa, F., Villalta, S., et al. (2015) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1544161 · Cited by 99
Bleeding after endoscopic submucosal dissection: Risk factors and preventive methods
Kataoka, Y., Tsuji, Y., Sakaguchi, Y., Minatsuki, C., Asada‐Hirayama, I., Niimi, K., Ono, S., Kodashima, S., Yamamichi, N., Fujishiro, M., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i26.5927 · Cited by 95
Deng, Q., Li, X. X., Fang, Y., Chen, X., & Xue, J. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/5926381 · Cited by 96
Implementation of a pharmacogenomics service in a community pharmacy
Ferreri, S. P., Greco, A. J., Michaels, N. M., O’Connor, S. K., Chater, R. W., Viera, A. J., Faruki, H., McLeod, H. L., & Roederer, M. W. (2014) · Journal of the American Pharmacists Association · doi:10.1331/japha.2014.13033 · Cited by 88
Lip, G. Y. H., Ponikowski, P., Andreotti, F., Anker, S. D., Filippatos, G., Homma, S., Morais, J., Pullicino, P. M., Rasmussen, L. H., Marín, F. R., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs073 · Cited by 89
Velangi, P. S., Choo, C., Chen, K.-H. A., Kazmirczak, F., Nijjar, P. S., Farzaneh‐Far, A., Okasha, O., Akçakaya, M., Weinsaft, J. W., & Shenoy, C. (2019) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.119.009723 · Cited by 84
Morales, D. R., Guthrie, B., Lipworth, B. J., Jackson, C., Donnan, P. T., & Santiago, V. H. (2015) · Allergy · doi:10.1111/all.12629 · Cited by 83
European guidelines on perioperative venous thromboembolism prophylaxis
Jenny, J., Pabinger, I., & Samama, C. M. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000728 · Cited by 84
The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review
Szczuko, M., Kozioł, I., Kotlęga, D., Brodowski, J., & Drozd, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111644 · Cited by 84
Solaymani–Dodaran, M., Card, T. R., & West, J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.050 · Cited by 75
Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment
Giosia, P. D., Passacquale, G., Petrarca, M., Giorgini, P., Marra, A. M., & Ferro, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.025 · Cited by 78
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?
Patrono, C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht058 · Cited by 76
Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review
Shiraev, T. P., & Bullen, A. S. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.10.020 · Cited by 74
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm
Ponikowski, P. P., Andreotti, F., Anker, S. D., Filippatos, G., Homma, S., Morais, J., Pullicino, P. M., Rasmussen, L., Marín, F. R., Lane, D. A., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0578 · Cited by 73
Mekaj, A., Mekaj, Y., & Daci, F. T. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s92222 · Cited by 73
Schaefer, J. K., Errickson, J., Li, Y., Kong, X., Alexandris-Souphis, T., Ali, M. A., DeCamillo, D., Haymart, B., Kaatz, S., Kline-Rogers, E. M., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.1197 · Cited by 74
Robson, R., Kundur, A., & Singh, I. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.12.029 · Cited by 70
Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity
Bonten, T. N., Saris, A., van Oostrom, M. J., Snoep, J. D., Rosendaal, F. R., Zwaginga, J., Eikenboom, J., van der Bom, J. G., & van der Bom, J. G. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-05-0453 · Cited by 73
Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease
Mora, S., & Manson, J. E. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2648 · Cited by 70
Hsu, S., Ton, V., Ashen, M. D., Martin, S. S., Gluckman, T. J., Kohli, P., Sisson, S. D., Blumenthal, R. S., & Blaha, M. J. (2013) · Clinical Cardiology · doi:10.1002/clc.22137 · Cited by 67
Schaefer, J. K., Li, Y., Gu, X., Souphis, N. M., Haymart, B., Kline-Rogers, E. M., ALMANY, S. L., Kaatz, S. S., Kozłowski, J., Krol, G. D., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.7816 · Cited by 65
Antiplatelet and Anticoagulant Agents in Heart Failure
Gurbel, P. A., & Tantry, U. S. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2013.07.007 · Cited by 66
Moriarty, F., Bennett, K., Fahey, T. P., Kenny, R. A., & Cahir, C. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1815-1 · Cited by 63
Patel, S. S., Guzmán, L. A., Lin, F., Pence, T. S., Reichman, T., John, B. V., Celi, F. S., Liptrap, E., Bhati, C. S., & Siddiqui, M. S. (2018) · Liver Transplantation · doi:10.1002/lt.25067 · Cited by 61
13. Diabetes Care in the Hospital, Nursing Home, and Skilled Nursing Facility
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s016 · Cited by 62
Azboy, İ., Groff, H., Goswami, K., Vahedian, M., & Parvizi, J. (2019) · The Journal of Arthroplasty · doi:10.1016/j.arth.2019.09.043 · Cited by 60
Metal-based nanoparticles: Promising tools for the management of cardiovascular diseases
Younis, N. K., Ghoubaira, J. A., Bassil, E. P., Tantawi, H. N., & Eid, A. H. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102433 · Cited by 64
Drug-Induced Thrombosis: An Update
Ramot, Y., Nyska, A., & Spectre, G. (2013) · Drug Safety · doi:10.1007/s40264-013-0054-6 · Cited by 59
Soden, P. A., Zettervall, S. L., Ultee, K. H. J., Landon, B. E., O’Malley, A. J., Goodney, P. P., DeMartino, R. R., Arya, S., & Schermerhorn, M. L. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2016.05.098 · Cited by 61
A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach?
Brotons, C., Benamouzig, R., Filipiak, K. J., Limmroth, V., & Borghi, C. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0100-5 · Cited by 58
VersorgungsLeitlinie, N. (2011) · Cited by 58
Androgen deprivation therapy complications
Allan, C. A., Collins, V., Frydenberg, M., McLachlan, R. I., & Matthiesson, K. L. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0467 · Cited by 55
Recovery Time of Platelet Function After Aspirin Withdrawal
Lee, J., Kim, J. K., Kim, J. H., Dunuu, T., Park, S., Park, S. J., Kang, J.-Y., Choi, R. K., & Hyon, M. S. (2014) · Current Therapeutic Research · doi:10.1016/j.curtheres.2014.02.002 · Cited by 55
Management of carotid stenosis in women
Rango, P. D., Brown, M. M., Leys, D., Howard, V. J., Moore, W. S., Paciaroni, M., Ringleb, P. A., Rockman, C. R., & Caso, V. (2013) · Neurology · doi:10.1212/wnl.0b013e318296e952 · Cited by 54
Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement
Spencer, F. A., Prasad, M., Vandvik, P. O., Chetan, D., Zhou, Q. X., & Guyatt, G. H. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0083 · Cited by 52
Self-citationNew Approaches to Inhibiting Platelets and Coagulation
Depta, J. P., & Bhatt, D. L. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124438 · Cited by 51
Montalescot, G., Lassen, J. F., Hamm, C. W., Lapostolle, F., Silvain, J., ten Berg, J. M., Cantor, W. J., Goodman, S. G., Licour, M., Tsatsaris, A., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2012.12.015 · Cited by 49
Nikpour, M., Gladman, D., & Urowitz, M. B. (2013) · Lupus · doi:10.1177/0961203313493031 · Cited by 50
Metadata
- Authors
- Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A.
- Affiliations
- Innlandet Hospital Trust (NO)
- Cleveland Clinic (US)
- University of Massachusetts Chan Medical School (US)
- Medical College of Wisconsin (US)
- University of Medicine and Dentistry of New Jersey (US)
- University at Buffalo, State University of New York (US)
- Stanford Medicine (US)
- McMaster University (CA)
- Corresponding author
- Spencer, Frederick A.
- ORCID
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 141
- Issue
- 2
- Pages
- e637S-e668S
- ISSN
- 0012-3692 (ISSN-L)
- PMC
- PMC3278064
- OpenAlex
- W2116051185
- Cited by
- 476
- References
- 118
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 11 · 2023: 6 · 2022: 23 · 2021: 19 · 2020: 32 · 2019: 36 · 2018: 29 · 2017: 44 · 2016: 46 · 2015: 59 · 2014: 58 · 2013: 64 · 2012: 37
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- CHEST Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Sanofi
- National Heart, Lung, and Blood Institute (R13HL104758)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- cardiovascular disease prevention, antithrombotic therapy, antiplatelet therapy, low-dose aspirin, clopidogrel, ticagrelor, prasugrel, dual antiplatelet therapy, single antiplatelet therapy, acute coronary syndrome, percutaneous coronary intervention, coronary artery disease, drug-eluting stents, bare-metal stents, long-term aspirin therapy
- MeSH terms
- Aged, Cardiovascular Diseases, Combined Modality Therapy, Coronary Disease, Dose-Response Relationship, Drug, Drug Therapy, Combination, Fibrinolytic Agents, Humans, Long-Term Care, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Societies, Medical, Thrombosis, Stents, Angioplasty, Balloon, Coronary, Myocardial Ischemia, Evidence-Based Medicine, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
